Advanced

Pooled analysis of prognostic impact of uPA and PAI-I in breast cancer patients

Look, M; van Putten, W; Duffy, M; Harbeck, N; Christensen, IJ; Thomssen, C; Kates, R; Spyratos, F; Fernö, Mårten LU and Eppenberger-Castori, S, et al. (2003) In Thrombosis and Haemostasis 90(3). p.538-548
Abstract
In this report we present an extension of the pooled analysis of the prognostic impact of urokinase-type plasminogen activator (uPA) and its inhibitor PAI-I in breast cancer patients. We analyzed a different endpoint, metastasis-free survival (MFS). We checked the consistency of the estimates for uPA and PAI-I for relapse-free survival (RFS) and MFS exploring possible sources of heterogeneity. Nodal status, the most important prognostic factor for breast cancer, introduced heterogeneity in the uPA/PAI-I survival analyses, reflecting the interaction between nodal status and uPA/PAI-I. The estimates for uPA and PAI-I were found to be consistent, even when a different transformation of their values was used. The heterogeneity of the separate... (More)
In this report we present an extension of the pooled analysis of the prognostic impact of urokinase-type plasminogen activator (uPA) and its inhibitor PAI-I in breast cancer patients. We analyzed a different endpoint, metastasis-free survival (MFS). We checked the consistency of the estimates for uPA and PAI-I for relapse-free survival (RFS) and MFS exploring possible sources of heterogeneity. Nodal status, the most important prognostic factor for breast cancer, introduced heterogeneity in the uPA/PAI-I survival analyses, reflecting the interaction between nodal status and uPA/PAI-I. The estimates for uPA and PAI-I were found to be consistent, even when a different transformation of their values was used. The heterogeneity of the separate data sets decreased if the levels of uPA and PAI-I were ranked, data sets were pooled, and the analyses corrected for the base model that included all traditional prognostic factors, and stratified by data set. We conclude that uPA and PAI-I are ready to be used in the clinic to help classify breast cancer patients into high and low risk groups. (Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
breast cancer, PAI-I, pooled-analysis, uPA, prognosis
in
Thrombosis and Haemostasis
volume
90
issue
3
pages
538 - 548
publisher
F K Schattauer Verlag Gmbh
external identifiers
  • wos:000185394200023
  • pmid:12958624
  • scopus:10744232822
ISSN
0340-6245
DOI
10.1160/TH02-11-0264
language
English
LU publication?
yes
id
f63e150d-4892-43a0-880e-279785140789 (old id 300732)
date added to LUP
2007-09-17 15:43:06
date last changed
2018-01-07 09:29:00
@article{f63e150d-4892-43a0-880e-279785140789,
  abstract     = {In this report we present an extension of the pooled analysis of the prognostic impact of urokinase-type plasminogen activator (uPA) and its inhibitor PAI-I in breast cancer patients. We analyzed a different endpoint, metastasis-free survival (MFS). We checked the consistency of the estimates for uPA and PAI-I for relapse-free survival (RFS) and MFS exploring possible sources of heterogeneity. Nodal status, the most important prognostic factor for breast cancer, introduced heterogeneity in the uPA/PAI-I survival analyses, reflecting the interaction between nodal status and uPA/PAI-I. The estimates for uPA and PAI-I were found to be consistent, even when a different transformation of their values was used. The heterogeneity of the separate data sets decreased if the levels of uPA and PAI-I were ranked, data sets were pooled, and the analyses corrected for the base model that included all traditional prognostic factors, and stratified by data set. We conclude that uPA and PAI-I are ready to be used in the clinic to help classify breast cancer patients into high and low risk groups.},
  author       = {Look, M and van Putten, W and Duffy, M and Harbeck, N and Christensen, IJ and Thomssen, C and Kates, R and Spyratos, F and Fernö, Mårten and Eppenberger-Castori, S and Sweep, CGJF and Ulm, K and Peyrat, JP and Martin, PM and Magdelenat, H and Brunner, N and Duggan, C and Lisboa, BW and Bendah, PO and Quillien, V and Daver, A and Ricolleau, G and Meijer-Van Gelder, M and Manders, P and Fiets, WE and Blankenstein, M and Broet, P and Romain, S and Daxenbichler, G and Windbichler, G and Cufer, T and Borstnar, S and Kueng, W and Beex, L and Klijn, J and O'Higgins, N and Eppenberger, U and Janicke, F and Schmitt, M and Foekens, J},
  issn         = {0340-6245},
  keyword      = {breast cancer,PAI-I,pooled-analysis,uPA,prognosis},
  language     = {eng},
  number       = {3},
  pages        = {538--548},
  publisher    = {F K Schattauer Verlag Gmbh},
  series       = {Thrombosis and Haemostasis},
  title        = {Pooled analysis of prognostic impact of uPA and PAI-I in breast cancer patients},
  url          = {http://dx.doi.org/10.1160/TH02-11-0264},
  volume       = {90},
  year         = {2003},
}